Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab by Tal Brosh-Nissimov, Nir Ma'aravi, Daniel Leshin-Carmel, Yonatan Edel, Sharon Ben Barouch, Yafit Segman, Amos Cahan, Erez Barenboim

Get full text

P571: OUTPATIENT INITIATION OF VENETOCLAX-AZACITIDINE FOR SELECTED ACUTE MYELOID LEUKEMIA PATIENTS IS FEASIBLE AND SAFE: A REAL WORLD SINGLE CENTER ANALYSIS by Roi Gat, Miri Neeman, Shai Levi, Mor Levi, Nili Eilati, Yotam Bronstein, Tamir Shragai, Tsipora Neuman, Yafit Segman, Roy Vitkon, Moshe Mittelman, Irit Avivi, Yakir Moshe

Get full text

P560: IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY. by Yakir Moshe, Shai Levi, Miri Neeman, Roi Gat, Mor Levi, Nili Eilati, Tamir Shragai, May Basood, Yafit Segman, Yaeli Baron, Efrat Luttwak, Tsipora Neuman, Roy Vitkon, Moshe Mittelman, Irit Avivi

Get full text

An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab by Tali Shafat, Daniel Grupel, Tzvika Porges, Ran Abuhasira, Ana Belkin, Ofir Deri, Yonatan Oster, Shadi Zahran, Ehud Horwitz, Netanel A. Horowitz, Hazim Khatib, Marjorie Vieira Batista, Anita Cassoli Cortez, Tal Brosh‐Nissimov, Yafit Segman, Linor Ishay, Regev Cohen, Alaa Atamna, Amy Spallone, Roy F. Chemaly, Juan Carlos Ramos‐Ramos, Michal Chowers, Evgeny Rogozin, Noga Carmi Oren, Şiran Keske, Orit Wolfovitz Barchad, Lior Nesher, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)

Get full text